Evidence map›Paper›PMID 28317534›Full record

ReviewDermatologic clinics2017

Vitiligo Pathogenesis and Emerging Treatments.

Mehdi Rashighi, John E Harris

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatologic clinics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05511493 (Efficacy of Platelet-rich Plasma With Fractional Erbium-YAG Laser Versus With Microneedling in Localized Stable Vitiligo), which is not on this map. Cited by 79 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05511493 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Efficacy of Platelet-rich Plasma With Fractional Erbium-YAG Laser Versus With Microneedling in Localized Stable Vitiligo

TypeinterventionalSponsorSouth Valley UniversityRan2022 to 2023Enrolled40ConditionsLocalized VitiligoArmsfractional Erbium-YAG laser, microneedling
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mehdi RashighiDepartment of Dermatology, University of Massachusetts Medical School, Worcester, MA 01605, USA; Department of Dermatology, Tehran University of Medical Sciences, 415 Taleqani Avenue, Tehran 1416613675, Iran.
John E HarrisDepartment of Dermatology, University of Massachusetts Medical School, Worcester, MA 01605, USA. Electronic address: John.Harris@umassmed.edu.

Funding

Treg Migration and Function During Autoimmunity within Peripheral TissueR01AR069114 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HARRIS, JOHN E · 2015 to 2020
$2.2M
NIAMS NIH HHS R01 AR069114
6 · The paper itself

Abstract

The pathogenesis of vitiligo involves interplay between intrinsic and extrinsic melanocyte defects, innate immune inflammation, and T-cell-mediated melanocyte destruction. The goal of treatment is to not only halt disease progression but also promote repigmentation through melanocyte regeneration, proliferation, and migration. Treatment strategies that address all aspects of disease pathogenesis and repigmentation are likely to have greatest efficacy, a strategy that may require combination therapies. Current treatments generally involve nontargeted suppression of autoimmunity, whereas emerging treatments are likely to use a more targeted approach based on in-depth understanding of disease pathogenesis, which may provide higher efficacy with a good safety profile.

Indexed as

Adaptive ImmunityAntioxidantsAutoimmunityHumansImmunity, InnateImmunosuppressive AgentsMelanocytesOxidative StressPhototherapyRegenerationSelf ToleranceT-Lymphocytes, CytotoxicVitiligoAntioxidantsImmunosuppressive AgentsAutoimmunityCellular stressChemokinesMelanogenesisTargeted therapyVitiligo

Identifiers

PMID28317534
PMCPMC5362109

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.